Circulating adiponectin levels following treatment can predict late clinical outcomes in chronic heart failure

Acta Cardiologica Sinica

Volumn 33, Issue 2, 2017, Pages 139-149

  Yu, Ho Ping ^a   Jen, Hsu Lung ^a,b   Yin, Wei Hsian ^a,c,d   Wei, Jeng ^a  

^a CHENG HSIN GENERAL HOSPITAL   (Taiwan)

^b Institute of Clinical Medicine   (Taiwan)

^c Faculty of Medicine   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Adiponectin; Chronic heart failure; Natriuretic peptide; Prognosis

Indexed keywords

ADIPONECTIN; ALPHA GLUCOSIDASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE; BRAIN NATRIURETIC PEPTIDE; DIGITALIS; DIURETIC AGENT; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MEGLITINIDE; SULFONYLUREA; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL OUTCOME; CONCENTRATION (PARAMETERS); ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROGNOSIS; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

EID: 85015657949     PISSN: 10116842     EISSN: None     Source Type: Journal    
DOI: 10.6515/ACS20160427B     Document Type: Article

References (33)

1. Sackner-Bernstein JD, Hart D. Neurohormonal antagonism in heart failure: what is the optimal strategy? Mt Sinai JMed 2004; 71:115-26.
2. Manabe I. Chronic inflammation links cardiovascular, metabolic and renal disease. Circ J 2011;75:2739-48.
3. Gullestad L, Ueland T, Vinge LE, et al. Inflammatory cytokines in heart failure: mediators and markers. Cardiology 2012;122:23-35.
4. Karmazyn M, Purdham DM, Rajapurohitam V, Zeidan A. Signalling mechanisms underlying the metabolic and other effects of adipokines on the heart. Cardiovasc Res 2008;79:279-86.
5. Yin WH, Wei J, Huang WP, et al. Prognostic value of circulating adipokine levels and expressions of adipokines in the myocardium of patients with chronic heart failure. Circ J 2012;76:2139-47.
6. Park M, Sweeney G. Direct effects of adipokines on the heart: focus on adiponectin. Heart Fail Rev 2013;18:631-44.
7. Conraads VM, Van Craenenbroeck EM, De Maeyer C, et al. Unraveling new mechanisms of exercise intolerance in chronic heart failure: role of exercise training. Heart Fail Rev 2013;18: 65-77.
8. Hatzis G, Deftereos S, Tousoulis D, et al. Adiponectin: merely a bystander or the missing link to cardiovascular disease? Curr Top Med Chem 2013;13:139-63.
9. Van Berendoncks AM, Garnier A, Ventura-Clapier R, Conraads VM. Adiponectin: key role and potential target to reverse energy wasting in chronic heart failure. Heart Fail Rev 2013;18:557-66.
10. Kistorp C, Faber J, Galatius S, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005;112:1756-62.
11. Tamura T, Furukawa Y, Taniguchi R, et al. Serum adiponectin level as an independent predictor of mortality in patients with congestive heart failure. Circ J 2007;71:623-30.
12. McEntegart MB, Awede B, Petrie MC, et al. Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur Heart J 2007;28:829-35.
13. Matsumoto M, Lee-Kawabata M, Tsujino T, et al. Decrease in serum adiponectin levels in response to treatment predicts good prognosis in acute decompensated heart failure. J Clin Hypertens (Greenwich) 2010;12:900-4.
14. Yamaji M, Tsutamoto T, Tanaka T, et al. Effect of carvedilol on plasma adiponectin concentration in patients with chronic heart failure. Circ J 2009;73:1067-73.
15. Van Berendoncks AM, Beckers P, Hoymans VY, et al. Betablockers modify the prognostic value of adiponectin in chronic heart failure. Int J Cardiol 2011;150:296-300.
16. Han SH, Quon MJ, Kim JA, Koh KK. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol 2007;49:531-8.
17. Koh KK, Quon MJ, Han SH, et al. Anti-inflammatory and metabolic effects of candesartan in hypertensive patients. Int J Cardiol 2006;108:96-100.
18. Furuhashi M, Ura N, Higashiura K, et al. Blockade of the reninangiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003;42:76-81.
19. Yu F, Chen R, Takahashi T, et al. Candesartan improvesmyocardial damage in obese mice with viralmyocarditis and induces cardiac adiponectin. Int J Cardiol 2008;129:414-21.
20. Lawlor DA, Davey Smith G, Ebrahim S, et al. Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab 2005;90:5677-83.
21. Sattar N, Wannamethee G, Sarwar N, et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 2006;114:623-9.
22. Goldstein BJ, Scalia RG, Ma XL. Protective vascular and myocardial effects of adiponectin. Nat Clin Pract Cardiovasc Med 2009; 6:27-35.
23. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001;98:2005-10.
24. Qi Y, Takahashi N, Hileman SM, et al. Adiponectin acts in the brain to decrease body weight. Nat Med 2004;10:524-9.
25. Hattori Y, Hattori S, Kasai K. Globular adiponectin activates nuclear factor-kappaB in vascular endothelial cells, which in turn induces expression of proinflammatory and adhesion molecule genes. Diabetes Care 2006;29:139-41.
26. Hattori Y, Hattori S, Akimoto K, et al. Globular adiponectin activates nuclear factor-kappaB and activating protein-1 and enhances angiotensin II-induced proliferation in cardiac fibroblasts. Diabetes 2007;56:804-8.
27. Sengenès C, Berlan M, De Glisezinski I, et al. Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J 2000;14: 1345-51.
28. Okamoto H. Can adiponectin be a novel metabolic biomarker for heart failure? Circ J 2009;73:1012-3.
29. Mentz RJ, Felker GM. Natriuretic peptide-guided therapy for heart failure. Circ J 2011;75:2031-7.
30. Li JJ, Xiang XL, Tian XY, Shi YF. Clinical research on brain natriuretic peptide guiding the application of 1 receptor blocker in patients with moderate to severe heart failure. Acta Cardiol Sin 2015;31:52-8.
31. Huang CH, Chien KL, Chen WJ, et al. Impact of heart failure and left ventricular function on long-term survival--report of a community- based cohort study in Taiwan. Eur J Heart Fail 2007;9: 587-93.
32. Tseng CH. Clinical features of heart failure hospitalization in younger and elderly patients in Taiwan. Eur J Clin Invest 2011; 41:597-604.
33. Mao CT, Liu MH, Hsu KH, et al. Effect of multidisciplinary disease management for hospitalized heart failure under a national health insurance programme. J Cardiovasc Med 2015;16:616-24.